[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652577":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":42,"responsibleParty":54,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":26,"overallStatus":75,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Al-Azhar University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Desmopressin plus bedtime device restriction","EXPERIMENTAL","Participants will receive oral desmopressin at bedtime for 8 weeks and will avoid digital-device use, including smartphones, tablets, televisions, computers, and video games, for at least 60 minutes before habitual bedtime.",[13,14],"Drug: Desmopressin","Behavioral: Bedtime digital-device restriction",{"label":16,"type":17,"description":18,"interventionNames":19},"Desmopressin only","ACTIVE_COMPARATOR","Participants will receive oral desmopressin at bedtime for 8 weeks and will continue their usual bedtime digital-device habits without restriction.",[13],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Desmopressin","Oral desmopressin administered at bedtime for 8 weeks for treatment of primary monosymptomatic nocturnal enuresis.",[16,9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"BEHAVIORAL","Bedtime digital-device restriction","Restriction of digital-device use, including smartphones, tablets, televisions, computers, and video games, for at least 60 minutes before habitual bedtime during the 8-week treatment period.",[9],[33],{"name":34,"affiliation":35,"role":36},"Abul-fotouh Ahmed","Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt","PRINCIPAL_INVESTIGATOR",[38],{"name":34,"role":39,"phone":40,"phoneExt":26,"email":41},"CONTACT","+201001066756","abulfotouhahmed@yahoo.com",[43],{"facility":44,"status":26,"city":45,"state":26,"zip":26,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":26},"Department of Urology, Al-Hussein and Sayed Galal University Hospitals, Al-Azhar University","Cairo","Egypt","EG",{"type":49,"coordinates":50},"Point",[51,52],31.24967,30.06263,{"lat":52,"lon":51},{"type":36,"investigatorFullName":34,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Principal Investigator","100652577","bedtime-device-restriction-and-desmopressin-in-pmne-100652577",false,"NCT07776977","Bedtime Device Restriction and Desmopressin in PMNE.","Effect of Bedtime Digital-Device Restriction on the Therapeutic Response to Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 6-14 years.\n* Diagnosis of PMNE (≥2 wet nights\u002Fweek for ≥6 months, no daytime symptoms, no prior sustained dryness \\>6 months).\n* Willingness to take oral desmopressin nightly for 8 weeks.\n* Parent\u002Fguardian able to monitor and report screen time and wet nights.\n* Written informed consent from parent\u002Fguardian and assent from child (if age-appropriate).\n\nExclusion Criteria:\n\n* Secondary enuresis or non-monosymptomatic enuresis (daytime incontinence, urgency, frequency).\n* Known organic causes (e.g., diabetes mellitus, urinary tract anomalies, neurological disorders).\n* Current use of other enuresis treatments (alarms, anticholinergics, imipramine) within 4 weeks prior to enrollment.\n* Severe sleep disorders (e.g., obstructive sleep apnea) or psychiatric conditions affecting compliance.\n* Inability to comply with study procedures or follow-up.","ALL","6 Years","14 Years",{"count":67,"type":68},140,"ESTIMATED","INTERVENTIONAL",[71],"NA","This randomized controlled trial will evaluate whether restricting bedtime digital-device use improves the response to desmopressin in children with primary monosymptomatic nocturnal enuresis. Participants will receive desmopressin for 8 weeks and will be assigned to either bedtime device restriction or usual screen habits.",[74],"Primary Monosymptomatic Nocturnal Enuresis","NOT_YET_RECRUITING","2026-08-18",{"date":78,"type":79},"2026-08-20","ACTUAL",{"date":81,"type":68},"2026-08",{"date":83,"type":68},"2027-07",{"name":5,"class":6},1]